NEW YORK (GenomeWeb) – Seattle-based Resolution Biosciences announced today that New York State's Clinical Laboratory Evaluation Program (NY CLEP) has granted regulatory approval for the company's ctDx Lung cancer assay, a targeted next-generation sequencing test that identifies actionable mutations in blood samples from non-small cell lung cancer patients.

President and CEO Mark Li said in a statement that the certification will allow Resolution to reach more patients, as well as ease the way for ongoing and planned clinical studies in New York.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Osamu Shimomura, who won the 2008 Nobel Prize in Chemistry for his work on green fluorescent protein, has died.

The US National Institutes of Health has developed guidelines to gauge whether frail chimpanzees are healthy enough to be move to a retirement sanctuary.

In PLOS this week: analytical approach for finding new genetic associations, analysis of Streptococcus pyogenes-infecting viruses, and more.

Stat News reports that the head of IBM Watson Health is leaving her post.